Gilead Sciences competitors and alternatives include Eli Lilly and Company, Johnson & Johnson, etc.…
Income Statement
Assets & Liabilities | Cash Flow
Profitability
Ratios
Valuation
| 2022 | 8852000000.00 |
|---|---|
| 2023 | 10496000000.00 |
| 2024 | 4434000000.00 |
| 2025 | 10820000000.00 |
| 2022 | 8660500000.00 |
|---|---|
| 2023 | 8567800000.00 |
| 2024 | 15227600000.00 |
| 2025 | 27936500000.00 |
| 2022 | 26605000000.00 |
|---|---|
| 2023 | 23320000000.00 |
| 2024 | 24781000000.00 |
| 2025 | 32581000000.00 |
| 2022 | 24174000000.00 |
|---|---|
| 2023 | 17172000000.00 |
| 2024 | 14910000000.00 |
| 2025 | 28293665000.00 |
| 2022 | 8344000000.00 |
|---|---|
| 2023 | 7421000000.00 |
| 2024 | 10305000000.00 |
| 2025 | 10019000000.00 |
| 2022 | 4600400000.00 |
|---|---|
| 2023 | -3152000000.00 |
| 2024 | 414300000.00 |
| 2025 | 8972000000.00 |
| 2022 | 17185000000.00 |
|---|---|
| 2023 | 18248000000.00 |
| 2024 | 19842000000.00 |
| 2025 | 19698000000.00 |
| 2022 | 24248000000.00 |
|---|---|
| 2023 | 22062000000.00 |
| 2024 | 17832000000.00 |
| 2025 | 0.00 |